A Phase 1/2 Placebo-Controlled Randomized Observer-Blind Dose-Finding Study to Describe the Safety Tolerability Immunogenicity and Potential Efficacy of SARS CoV 2 RNA Vaccine Candidates Against COVID 19 in Healthy Adults

Brief description of study

The World Health Organization (WHO) has declared COVID-19 to be a pandemic; finding a vaccine to prevent COVID-19 is an urgent need. The study will compare the results of the people who receive the study vaccine with those who receive a placebo (a placebo does not contain any active ingredients). Participants will be assigned to one of the groups investigating one of the study vaccines, at one of the vaccine dose levels. All groups will have some people who get 2 placebo injections.

Clinical Study Identifier: s20-00515
ClinicalTrials.gov Identifier: NCT04368728
Principal Investigator: Mark J. Mulligan
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.